RU2015145543A - Способы и композиции для лечения болезни дего - Google Patents
Способы и композиции для лечения болезни дего Download PDFInfo
- Publication number
- RU2015145543A RU2015145543A RU2015145543A RU2015145543A RU2015145543A RU 2015145543 A RU2015145543 A RU 2015145543A RU 2015145543 A RU2015145543 A RU 2015145543A RU 2015145543 A RU2015145543 A RU 2015145543A RU 2015145543 A RU2015145543 A RU 2015145543A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- composition
- fragment
- interferon alpha
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
Claims (15)
1. Композиция, содержащая (i) ингибитор комплемента и (ii) ингибитор интерферона альфа.
2. Композиция по п. 1, где ингибитор комплемента представляет собой антитело или его антигенсвязывающий фрагмент, которые связываются с белком компонента С5 комплемента человека.
3. Композиция по п. 2, где антитело или его антигенсвязывающий фрагмент ингибируют расщепление компонента С5 комплемента на фрагменты C5a и C5b.
4. Композиция по п. 2, где антитело или его антигенсвязывающий фрагмент выбирают из группы, состоящей из гуманизированного антитела, рекомбинантного антитела, диатела, химеризованного или химерного антитела, деиммунизованного антитела человека, полностью человеческого антитела, одноцепочечного антитела, фрагмента Fv, фрагмента Fd, фрагмента Fab, фрагмента Fab’ и фрагмента F(ab')2.
5. Композиция по п. 1, где антитело представляет собой экулизумаб.
6. Композиция по п. 1, где антитело представляет собой пекселизумаб.
7. Композиция по п. 1, где ингибитор интерферона альфа представляет собой антитело или его антигенсвязывающий фрагмент, которые связываются с интерфероном альфа или рецептором интерферона альфа.
8. Композиция по п. 7, где антитело или его антигенсвязывающий фрагмент, которые связываются с интерфероном альфа или рецептором интерферона альфа, выбирают из группы, состоящей из моноклонального антитела, гуманизированного антитела, рекомбинантного антитела, диатела, химеризованного или химерного антитела, деиммунизованного антитела человека, полностью человеческого антитела, одноцепочечного антитела, фрагмента Fv, фрагмента Fd, фрагмента Fab, фрагмента Fab’ и фрагмента F(ab')2.
9. Композиция по п. 1, где композиция составлена для парентерального введения.
10. Композиция по п. 1, дополнительно содержащая иммуносупрессирующее средство.
11. Композиция по п. 10, где иммуносупрессирующее средство выбирают из группы, состоящей из кортикостероидов, фенилбутазона, азатиоприна, метотрексата, циклоспорина, такролимуса и микофенолата мофетила, циклофосфамида и агента против CD20.
12. Композиция по п. 1, дополнительно содержащая второй ингибитор интерферона альфа.
13. Набор, содержащий ингибитор комплемента, ингибитор интерферона альфа и контейнер с этикеткой.
14. Набор по п. 13, где ингибитор комплемента и ингибитор интерферона альфа составлены раздельно.
15. Набор по п. 13, где ингибитор комплемента и ингибитор интерферона альфа составлены вместе.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30939310P | 2010-03-01 | 2010-03-01 | |
| US61/309,393 | 2010-03-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012141556/15A Division RU2570390C2 (ru) | 2010-03-01 | 2011-03-01 | Способы и композиции для лечения болезни дего |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015145543A3 RU2015145543A3 (ru) | 2019-01-11 |
| RU2015145543A true RU2015145543A (ru) | 2019-01-11 |
Family
ID=44542525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012141556/15A RU2570390C2 (ru) | 2010-03-01 | 2011-03-01 | Способы и композиции для лечения болезни дего |
| RU2015145543A RU2015145543A (ru) | 2010-03-01 | 2011-03-01 | Способы и композиции для лечения болезни дего |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012141556/15A RU2570390C2 (ru) | 2010-03-01 | 2011-03-01 | Способы и композиции для лечения болезни дего |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8999340B2 (ru) |
| EP (1) | EP2542255B1 (ru) |
| JP (3) | JP5852021B2 (ru) |
| KR (1) | KR20130009784A (ru) |
| CN (1) | CN102985106A (ru) |
| AU (1) | AU2011223866B2 (ru) |
| BR (1) | BR112012022214A2 (ru) |
| CA (1) | CA2791962A1 (ru) |
| ES (1) | ES2615732T3 (ru) |
| MX (1) | MX2012010116A (ru) |
| NZ (1) | NZ602219A (ru) |
| RU (2) | RU2570390C2 (ru) |
| SG (1) | SG183541A1 (ru) |
| WO (1) | WO2011109338A1 (ru) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| PL2698166T3 (pl) | 2006-10-10 | 2016-03-31 | Regenesance B V | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
| WO2009041643A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
| JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| RU2570390C2 (ru) * | 2010-03-01 | 2015-12-10 | Алексион Фармасьютикалз Инк. | Способы и композиции для лечения болезни дего |
| EP4231014A3 (en) | 2010-11-30 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| RU2662563C2 (ru) | 2011-04-08 | 2018-07-26 | Юниверсити Оф Лестер | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
| JP6276202B2 (ja) | 2012-02-20 | 2018-02-07 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合するポリペプチド |
| AU2013334229B2 (en) | 2012-10-25 | 2018-02-15 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2014110438A1 (en) * | 2013-01-11 | 2014-07-17 | Alexion Pharmaceuticals, Inc. | Compounds and methods related to the c5d domain of complement component c5 |
| WO2014119969A1 (ko) * | 2013-01-31 | 2014-08-07 | 서울대학교 산학협력단 | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 |
| MX366660B (es) | 2013-03-14 | 2019-07-18 | Alnylam Pharmaceuticals Inc | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. |
| JP6505079B2 (ja) | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| WO2015039126A1 (en) | 2013-09-16 | 2015-03-19 | Children hospital medical center | Compositions and methods for treatment of hsct-associated thrombotic microangiopathy |
| HUE051746T2 (hu) | 2013-10-17 | 2021-03-29 | Omeros Corp | Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| US20160108357A1 (en) * | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of culturing a cell |
| WO2016061066A1 (en) | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
| EA201791366A1 (ru) * | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| HUE061076T2 (hu) | 2015-04-06 | 2023-05-28 | Bioverativ Usa Inc | Humanizált anti-C1s ellenanyagok alkalmazási eljárások |
| EP3307318A4 (en) | 2015-06-09 | 2019-01-16 | Children's Hospital Medical Center | DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR |
| CA2997745A1 (en) | 2015-09-14 | 2017-03-23 | Children's Hospital Medical Center | Methods and compositions for treatment of gaucher disease via modulation of c5a receptor |
| SG10201709415WA (en) | 2015-12-18 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| MY196220A (en) | 2016-06-14 | 2023-03-23 | Regeneron Pharma | Anti-C5 Antibodies and uses Thereof |
| KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| US20200369763A1 (en) * | 2017-12-01 | 2020-11-26 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| WO2019118556A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| CN103145842A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| US20070292421A1 (en) * | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| EP3037544A1 (en) * | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases |
| US20110130544A1 (en) * | 2007-03-30 | 2011-06-02 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
| MX343167B (es) * | 2007-05-21 | 2016-10-26 | Genentech Inc * | Metodos y composiciones para identificar y tratar lupus. |
| WO2009149306A2 (en) | 2008-06-04 | 2009-12-10 | Incode Biopharmaceutics, Inc. | Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds |
| WO2010054403A1 (en) | 2008-11-10 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| US20110002931A1 (en) * | 2009-06-23 | 2011-01-06 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| RU2570390C2 (ru) * | 2010-03-01 | 2015-12-10 | Алексион Фармасьютикалз Инк. | Способы и композиции для лечения болезни дего |
-
2011
- 2011-03-01 RU RU2012141556/15A patent/RU2570390C2/ru not_active IP Right Cessation
- 2011-03-01 JP JP2012556156A patent/JP5852021B2/ja active Active
- 2011-03-01 NZ NZ602219A patent/NZ602219A/en not_active IP Right Cessation
- 2011-03-01 MX MX2012010116A patent/MX2012010116A/es active IP Right Grant
- 2011-03-01 EP EP11751164.2A patent/EP2542255B1/en active Active
- 2011-03-01 RU RU2015145543A patent/RU2015145543A/ru unknown
- 2011-03-01 KR KR1020127024302A patent/KR20130009784A/ko not_active Application Discontinuation
- 2011-03-01 CA CA2791962A patent/CA2791962A1/en not_active Abandoned
- 2011-03-01 SG SG2012064150A patent/SG183541A1/en unknown
- 2011-03-01 CN CN2011800220097A patent/CN102985106A/zh active Pending
- 2011-03-01 AU AU2011223866A patent/AU2011223866B2/en not_active Ceased
- 2011-03-01 WO PCT/US2011/026602 patent/WO2011109338A1/en active Application Filing
- 2011-03-01 BR BR112012022214A patent/BR112012022214A2/pt not_active IP Right Cessation
- 2011-03-01 US US13/582,018 patent/US8999340B2/en active Active
- 2011-03-01 ES ES11751164.2T patent/ES2615732T3/es active Active
-
2015
- 2015-03-04 US US14/638,636 patent/US20150174243A1/en not_active Abandoned
- 2015-11-04 JP JP2015216557A patent/JP2016026217A/ja not_active Withdrawn
- 2015-11-04 JP JP2015216556A patent/JP2016026216A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015145543A3 (ru) | 2019-01-11 |
| MX2012010116A (es) | 2013-02-26 |
| EP2542255A4 (en) | 2013-07-31 |
| JP2016026217A (ja) | 2016-02-12 |
| NZ602219A (en) | 2014-10-31 |
| JP5852021B2 (ja) | 2016-02-03 |
| JP2013521294A (ja) | 2013-06-10 |
| US20130064820A1 (en) | 2013-03-14 |
| SG183541A1 (en) | 2012-10-30 |
| BR112012022214A2 (pt) | 2017-07-04 |
| RU2570390C2 (ru) | 2015-12-10 |
| RU2012141556A (ru) | 2014-04-10 |
| US8999340B2 (en) | 2015-04-07 |
| CA2791962A1 (en) | 2011-09-09 |
| AU2011223866A1 (en) | 2012-09-27 |
| JP2016026216A (ja) | 2016-02-12 |
| KR20130009784A (ko) | 2013-01-23 |
| CN102985106A (zh) | 2013-03-20 |
| US20150174243A1 (en) | 2015-06-25 |
| EP2542255B1 (en) | 2016-11-16 |
| WO2011109338A1 (en) | 2011-09-09 |
| ES2615732T3 (es) | 2017-06-08 |
| EP2542255A1 (en) | 2013-01-09 |
| AU2011223866B2 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015145543A (ru) | Способы и композиции для лечения болезни дего | |
| JP2013198490A5 (ru) | ||
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| JP2018513149A5 (ru) | ||
| JP2013545738A5 (ru) | ||
| JP2013538057A5 (ru) | ||
| JP2009509538A5 (ru) | ||
| JP2020535799A5 (ru) | ||
| JP2020508655A5 (ru) | ||
| RU2016132757A (ru) | Антитела, направленные против интерлейкина-33 (il-33) | |
| JP2012526558A5 (ru) | ||
| RU2013125457A (ru) | Комбинация антител против с-мет | |
| JP2014526898A5 (ru) | ||
| JP2015533853A5 (ru) | ||
| JP2013091655A5 (ru) | ||
| JP2017504577A5 (ru) | ||
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2015525795A5 (ru) | ||
| JP2006502699A5 (ru) | ||
| JP2011526249A5 (ru) | ||
| JP2008529529A5 (ru) | ||
| RU2010132956A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2012532851A5 (ru) | ||
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| JP2014529610A5 (ru) |